[
  {
    "ts": "2026-02-17T05:06:14+00:00",
    "headline": "Eli Lilly (LLY) Valuation Check After Positive Phase 3 Retevmo Results And GLP 1 Growth Momentum",
    "summary": "Eli Lilly (LLY) is back in focus after reporting statistically significant Phase 3 results for Retevmo in early stage RET fusion positive lung cancer, adding another clinical milestone to an already closely watched story. See our latest analysis for Eli Lilly. Against a backdrop of strong GLP 1 obesity and diabetes demand, upbeat 2026 revenue guidance and ongoing buybacks, Eli Lilly’s 1 year total shareholder return of 24.1% and very large 5 year total shareholder return of about 4.4x suggest...",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-valuation-check-050614389.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "479ee86d-de25-3759-b84e-5c1e7bf2cf79",
      "content": {
        "id": "479ee86d-de25-3759-b84e-5c1e7bf2cf79",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Valuation Check After Positive Phase 3 Retevmo Results And GLP 1 Growth Momentum",
        "description": "",
        "summary": "Eli Lilly (LLY) is back in focus after reporting statistically significant Phase 3 results for Retevmo in early stage RET fusion positive lung cancer, adding another clinical milestone to an already closely watched story. See our latest analysis for Eli Lilly. Against a backdrop of strong GLP 1 obesity and diabetes demand, upbeat 2026 revenue guidance and ongoing buybacks, Eli Lilly’s 1 year total shareholder return of 24.1% and very large 5 year total shareholder return of about 4.4x suggest...",
        "pubDate": "2026-02-17T05:06:14Z",
        "displayTime": "2026-02-17T05:06:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-valuation-check-050614389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-valuation-check-050614389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T09:53:58+00:00",
    "headline": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says",
    "summary": "By Rishika Sadam and Kashish Tandon HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as",
    "url": "https://finance.yahoo.com/news/lilly-targets-india-global-export-094912443.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "ef69071a-653c-3cf8-bb6f-68a439295705",
      "content": {
        "id": "ef69071a-653c-3cf8-bb6f-68a439295705",
        "contentType": "STORY",
        "title": "Lilly targets India as global export hub amid booming Mounjaro sales, executive says",
        "description": "",
        "summary": "By Rishika Sadam and Kashish Tandon HYDERABAD, Feb 17 (Reuters) - Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as",
        "pubDate": "2026-02-17T09:53:58Z",
        "displayTime": "2026-02-17T09:53:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/12c16a4701a4370e62353243fd45d307",
          "originalWidth": 800,
          "originalHeight": 555,
          "caption": "Visitors stand at the kiosk of Eli Lilly at the BioAsia conference in Hyderabad, India, February 17, 2026. Picture taken with a mobile phone. REUTERS/Sriparna Roy",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LaVH8My_FiH8DJaTBmf_ww--~B/aD01NTU7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/12c16a4701a4370e62353243fd45d307.cf.webp",
              "width": 800,
              "height": 555,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ETOYaUIPUkRQ0osUfmwUAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/12c16a4701a4370e62353243fd45d307.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-targets-india-global-export-094912443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-targets-india-global-export-094912443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:59:15+00:00",
    "headline": "Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market",
    "summary": "LLY Prepares Big Launch for Oral Orforglipron. Competes With Novo Nordisk's Wegovy in Weight-Loss Market.",
    "url": "https://finance.yahoo.com/news/eli-lilly-stock-rises-1-135915577.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "21d56a56-9828-3df5-9adc-837d598cb836",
      "content": {
        "id": "21d56a56-9828-3df5-9adc-837d598cb836",
        "contentType": "STORY",
        "title": "Eli Lilly Stock Rises as $1.5 Billion Weight-Loss Pill Prepares to Hit Market",
        "description": "",
        "summary": "LLY Prepares Big Launch for Oral Orforglipron. Competes With Novo Nordisk's Wegovy in Weight-Loss Market.",
        "pubDate": "2026-02-17T13:59:15Z",
        "displayTime": "2026-02-17T13:59:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-rises-1-135915577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-stock-rises-1-135915577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:37:11+00:00",
    "headline": "Eli Lilly Targets India as Global Export Hub Amid Surging Mounjaro Sales",
    "summary": "Company plans to scale $1 billion investment as weight-loss demand accelerates.",
    "url": "https://finance.yahoo.com/news/eli-lilly-targets-india-global-133711401.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "fc891e4e-058f-3c86-8eb0-9b7b6c8a2502",
      "content": {
        "id": "fc891e4e-058f-3c86-8eb0-9b7b6c8a2502",
        "contentType": "STORY",
        "title": "Eli Lilly Targets India as Global Export Hub Amid Surging Mounjaro Sales",
        "description": "",
        "summary": "Company plans to scale $1 billion investment as weight-loss demand accelerates.",
        "pubDate": "2026-02-17T13:37:11Z",
        "displayTime": "2026-02-17T13:37:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-targets-india-global-133711401.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-targets-india-global-133711401.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:00:00+00:00",
    "headline": "Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company",
    "summary": "ALAMEDA, Calif., February 17, 2026--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company",
    "url": "https://finance.yahoo.com/news/scribe-therapeutics-achieves-second-success-130000667.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "2cc10b68-13f5-3cd2-834a-dbbf47a32968",
      "content": {
        "id": "2cc10b68-13f5-3cd2-834a-dbbf47a32968",
        "contentType": "STORY",
        "title": "Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company",
        "description": "",
        "summary": "ALAMEDA, Calif., February 17, 2026--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company",
        "pubDate": "2026-02-17T13:00:00Z",
        "displayTime": "2026-02-17T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01",
          "originalWidth": 2937,
          "originalHeight": 807,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ifPBxklVPfQWRMt9MzCscw--~B/aD04MDc7dz0yOTM3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01.cf.webp",
              "width": 2937,
              "height": 807,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T_SRXnEVO.ZnOjhSkzL94Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9e0012b3318dee45c22f366152a08c01.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/scribe-therapeutics-achieves-second-success-130000667.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/scribe-therapeutics-achieves-second-success-130000667.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:57:00+00:00",
    "headline": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
    "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
    "url": "https://finance.yahoo.com/news/abbvie-down-since-q4-earnings-135700742.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e7689a26-8206-3d87-b7f0-c6f3b05cdb88",
      "content": {
        "id": "e7689a26-8206-3d87-b7f0-c6f3b05cdb88",
        "contentType": "STORY",
        "title": "AbbVie Down Since Q4 Earnings Report: How to Play the Stock",
        "description": "",
        "summary": "ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.",
        "pubDate": "2026-02-17T13:57:00Z",
        "displayTime": "2026-02-17T13:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WtA490SSyXq.BB5XEEYFSg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BdQSUWaJAMCKg7gp75c9jQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-down-since-q4-earnings-135700742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-down-since-q4-earnings-135700742.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T16:09:32+00:00",
    "headline": "Eli Lilly Advances Gene Editing And Lung Cancer Programs With Valuation Upside",
    "summary": "Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported positive topline Phase 3 LIBRETTO-432 results for Retevmo in RET fusion positive early-stage non small cell lung cancer. Both updates point to progress in genetic medicines and targeted oncology for patients with high medical need. Eli Lilly sits at the intersection of large scale...",
    "url": "https://finance.yahoo.com/news/eli-lilly-advances-gene-editing-160932950.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d4fcdf63-f2e8-31f8-88b7-f20d873bc4c7",
      "content": {
        "id": "d4fcdf63-f2e8-31f8-88b7-f20d873bc4c7",
        "contentType": "STORY",
        "title": "Eli Lilly Advances Gene Editing And Lung Cancer Programs With Valuation Upside",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported positive topline Phase 3 LIBRETTO-432 results for Retevmo in RET fusion positive early-stage non small cell lung cancer. Both updates point to progress in genetic medicines and targeted oncology for patients with high medical need. Eli Lilly sits at the intersection of large scale...",
        "pubDate": "2026-02-17T16:09:32Z",
        "displayTime": "2026-02-17T16:09:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-advances-gene-editing-160932950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-advances-gene-editing-160932950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T16:04:36+00:00",
    "headline": "Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk",
    "summary": "Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.",
    "url": "https://www.investors.com/news/technology/hims-stock-compounded-semaglutide-oral-novo-nordisk-fda/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "c4ab0c64-09af-388e-a321-56dbd64c2866",
      "content": {
        "id": "c4ab0c64-09af-388e-a321-56dbd64c2866",
        "contentType": "STORY",
        "title": "Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk",
        "description": "",
        "summary": "Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.",
        "pubDate": "2026-02-17T16:04:36Z",
        "displayTime": "2026-02-17T16:04:36Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c4ab0c64-09af-388e-a321-56dbd64c2866/hims-hers-faces-new-hurdle.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/a25a163db3ec3a190106ca8c665184de",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WQaD7ik_eMrnRSclzUE_9w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/a25a163db3ec3a190106ca8c665184de.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LnM4Pd9H7PIZMmWx6zQOaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/a25a163db3ec3a190106ca8c665184de.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/hims-stock-compounded-semaglutide-oral-novo-nordisk-fda/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T17:35:00+00:00",
    "headline": "1 Reason I'd Buy Eli Lilly Stock and Never Sell",
    "summary": "A robust pipeline is essential for a buy-and-hold pharmaceutical stock.",
    "url": "https://www.fool.com/investing/2026/02/17/1-reason-id-buy-eli-lilly-stock-and-never-sell/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ac11d3bd-58b3-3edf-9f5c-189b825cf821",
      "content": {
        "id": "ac11d3bd-58b3-3edf-9f5c-189b825cf821",
        "contentType": "STORY",
        "title": "1 Reason I'd Buy Eli Lilly Stock and Never Sell",
        "description": "",
        "summary": "A robust pipeline is essential for a buy-and-hold pharmaceutical stock.",
        "pubDate": "2026-02-17T17:35:00Z",
        "displayTime": "2026-02-17T17:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ed8280e921e33a67e1e2ec65b76581e8",
          "originalWidth": 1400,
          "originalHeight": 834,
          "caption": "Dice that spell out FDA Approved.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mPHD9Ce3sWDFMFmeBZ486Q--~B/aD04MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ed8280e921e33a67e1e2ec65b76581e8.cf.webp",
              "width": 1400,
              "height": 834,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a9f83HB015MvYjzCqn_8aw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ed8280e921e33a67e1e2ec65b76581e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/17/1-reason-id-buy-eli-lilly-stock-and-never-sell/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-id-buy-eli-173500920.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T20:36:40+00:00",
    "headline": "Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More",
    "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.",
    "url": "https://www.fool.com/coverage/filings/2026/02/17/kymera-therapeutics-stock-up-120-in-1-year-as-fund-adds-usd3-million-more/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e5b3f179-ae6f-3804-929e-61f3eba150f4",
      "content": {
        "id": "e5b3f179-ae6f-3804-929e-61f3eba150f4",
        "contentType": "STORY",
        "title": "Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More",
        "description": "",
        "summary": "Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.",
        "pubDate": "2026-02-17T20:36:40Z",
        "displayTime": "2026-02-17T20:36:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b04bb06bf39e9585a2b2b9bd7fd9773e",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R1oDutaLDH67fRkLZiZhnw--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b04bb06bf39e9585a2b2b9bd7fd9773e.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HA9HekYlkgeyrr1CrthasA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b04bb06bf39e9585a2b2b9bd7fd9773e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/17/kymera-therapeutics-stock-up-120-in-1-year-as-fund-adds-usd3-million-more/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kymera-therapeutics-stock-120-1-203640205.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "TVTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T20:58:22+00:00",
    "headline": "Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash",
    "summary": "Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.",
    "url": "https://www.fool.com/coverage/filings/2026/02/17/agios-stock-down-16-in-a-year-as-fund-cuts-stake-by-usd5-6-million-after-50-november-crash/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d71d4bd0-683c-33f7-8844-d264f7eb8654",
      "content": {
        "id": "d71d4bd0-683c-33f7-8844-d264f7eb8654",
        "contentType": "STORY",
        "title": "Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash",
        "description": "",
        "summary": "Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.",
        "pubDate": "2026-02-17T20:58:22Z",
        "displayTime": "2026-02-17T20:58:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/fc4e7308bab84ca64d2d9b8ed6703ee0",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e09iYXfg207s9Tq26Z8Zuw--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/fc4e7308bab84ca64d2d9b8ed6703ee0.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kw40AFrYJ3HgenDdq8_ZVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/fc4e7308bab84ca64d2d9b8ed6703ee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/17/agios-stock-down-16-in-a-year-as-fund-cuts-stake-by-usd5-6-million-after-50-november-crash/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agios-stock-down-16-fund-205822840.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AGIO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T20:48:00+00:00",
    "headline": "Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million",
    "summary": "This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.",
    "url": "https://www.fool.com/coverage/filings/2026/02/17/cogent-biosciences-stock-soars-346-in-a-year-but-one-fund-just-sold-off-usd4-5-million/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "fe84b26d-b24d-366b-93f9-520899541be7",
      "content": {
        "id": "fe84b26d-b24d-366b-93f9-520899541be7",
        "contentType": "STORY",
        "title": "Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million",
        "description": "",
        "summary": "This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.",
        "pubDate": "2026-02-17T20:48:00Z",
        "displayTime": "2026-02-17T20:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/bcedb4b0520262800bd36f45885c84ce",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ewvwb1C7iKrkXCir6TMF9w--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/bcedb4b0520262800bd36f45885c84ce.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZMmVtFcO8g6xD3NNN2rOkg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/bcedb4b0520262800bd36f45885c84ce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/17/cogent-biosciences-stock-soars-346-in-a-year-but-one-fund-just-sold-off-usd4-5-million/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cogent-biosciences-stock-soars-346-204800524.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "COGT"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "TVTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T20:42:30+00:00",
    "headline": "Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake",
    "summary": "Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.",
    "url": "https://www.fool.com/coverage/filings/2026/02/17/structure-therapeutics-stock-up-187-in-one-year-as-fund-trims-usd8-million-from-stake/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e1ea5cb7-32df-3eaf-902b-1f0adb6b4fb3",
      "content": {
        "id": "e1ea5cb7-32df-3eaf-902b-1f0adb6b4fb3",
        "contentType": "STORY",
        "title": "Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake",
        "description": "",
        "summary": "Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.",
        "pubDate": "2026-02-17T20:42:30Z",
        "displayTime": "2026-02-17T20:42:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/a8956053d80d7d218a78088a7252881c",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0JIjtLRnd_KE4bXsoXwH3g--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a8956053d80d7d218a78088a7252881c.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ldIib1jW.ap.AxJqiG6mRw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a8956053d80d7d218a78088a7252881c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/17/structure-therapeutics-stock-up-187-in-one-year-as-fund-trims-usd8-million-from-stake/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/structure-therapeutics-stock-187-one-204230034.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GPCR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]